Amgen (Europe) GmbH
Amgen (Europe) GmbH, a subsidiary of the global biotechnology leader Amgen Inc., is headquartered in Switzerland (CH) and operates extensively across Europe. Founded in 1980, Amgen has established itself as a pioneer in the biotechnology industry, focusing on innovative therapies for serious illnesses. The company is renowned for its core products, including biologics and biosimilars, which address conditions such as cancer, kidney disease, and inflammatory disorders. Amgen's commitment to research and development has led to significant milestones, including the introduction of groundbreaking treatments that enhance patient outcomes. With a strong market position, Amgen (Europe) GmbH is recognised for its contributions to healthcare, consistently striving to deliver unique solutions that improve lives. Its dedication to scientific excellence and patient-centric approaches solidifies its reputation as a leader in the biopharmaceutical sector.
DitchCarbon Score
How does Amgen (Europe) GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amgen (Europe) GmbH's score of 33 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amgen (Europe) GmbH's reported carbon emissions
Amgen (Europe) GmbH, headquartered in Switzerland (CH), currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. In the absence of specific emissions data, it is important to note that many companies in the biopharmaceutical industry are increasingly focusing on sustainability and climate commitments. This often includes setting science-based targets for reducing greenhouse gas emissions across various scopes, including Scope 1 (direct emissions), Scope 2 (indirect emissions from energy), and Scope 3 (indirect emissions from the value chain). While Amgen (Europe) GmbH has not disclosed its specific commitments or achievements in this area, the industry trend indicates a growing emphasis on reducing carbon footprints and enhancing environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amgen (Europe) GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
